27589720|t|Ruscogenin Attenuates Cerebral Ischemia -Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP / NLRP3 Inflammasome Activation and the MAPK Pathway
27589720|a|Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, has been shown to inhibit cerebral ischemic injury. However, its potential molecular action on blood-brain barrier (BBB) dysfunction after stroke remains unclear. This study aimed to investigate the effects of ruscogenin on BBB dysfunction and the underlying mechanisms in middle cerebral artery occlusion / reperfusion (MCAO / R)- injured mice and oxygen-glucose deprivation / reoxygenation (OGD / R)- injured mouse brain microvascular endothelial cells (bEnd.3). The results demonstrated that administration of ruscogenin (10 mg/kg) decreased the brain infarction and edema, improved neurological deficits, increased cerebral brain flow (CBF), ameliorated histopathological damage, reduced evans blue (EB) leakage and upregulated the expression of tight junctions (TJs) in MCAO / R - injured mice. Meanwhile, ruscogenin (0.1-10 µM) treatment increased cell viability and trans-endothelial electrical resistance (TEER) value, decreased sodium fluorescein leakage, and modulated the TJs expression in OGD / R -induced bEnd.3 cells. Moreover, ruscogenin also inhibited the expression of interleukin-1β (IL-1β) and caspase-1, and markedly suppressed the expression of Nucleotide-binding domain (NOD)-like receptor family, pyrin domain containing 3 (NLRP3) and thiredoxin-interactive protein (TXNIP) in vivo and in vitro. Furthermore, ruscogenin decreased reactive oxygen species (ROS) generation and inhibited the mitogen-activated protein kinase (MAPK) pathway in OGD / R -induced bEnd.3 cells. Our findings provide some new insights into its potential application for the prevention and treatment of ischemic stroke.
27589720	0	10	Ruscogenin	T109,T121,T123	C0073709
27589720	11	21	Attenuates	T052	C0599946
27589720	22	39	Cerebral Ischemia	T047	C0917798
27589720	49	68	Blood-Brain Barrier	T023	C0005854
27589720	69	80	Dysfunction	T077	C3887504
27589720	84	95	Suppressing	T169	C1260953
27589720	96	101	TXNIP	T116,T123	C1448239
27589720	104	133	NLRP3 Inflammasome Activation	T044	C3272080
27589720	142	154	MAPK Pathway	T043	C1518102
27589720	155	165	Ruscogenin	T109,T121,T123	C0073709
27589720	170	179	important	T080	C3898777
27589720	180	187	steroid	T109	C0038317
27589720	188	197	sapogenin	T109	C0072845
27589720	198	210	derived from	T078	C1550535
27589720	211	231	Ophiopogon japonicus	T002	C1046253
27589720	251	258	inhibit	T052	C3463820
27589720	259	283	cerebral ischemic injury	T037	C2945681
27589720	298	307	potential	T080	C3245505
27589720	308	324	molecular action	T044	C1148560
27589720	328	347	blood-brain barrier	T023	C0005854
27589720	349	352	BBB	T023	C0005854
27589720	354	365	dysfunction	T077	C3887504
27589720	372	378	stroke	T047	C0038454
27589720	387	394	unclear	T033	C3845108
27589720	401	406	study	T062	C2603343
27589720	407	412	aimed	T078	C1947946
27589720	416	427	investigate	T169	C1292732
27589720	432	439	effects	T080	C1280500
27589720	443	453	ruscogenin	T109,T121,T123	C0073709
27589720	457	460	BBB	T023	C0005854
27589720	461	472	dysfunction	T077	C3887504
27589720	492	502	mechanisms	T169	C0441712
27589720	506	538	middle cerebral artery occlusion	T020	C0740391
27589720	541	552	reperfusion	T037	C3854511
27589720	554	558	MCAO	T020	C0740391
27589720	561	562	R	T037	C3854511
27589720	565	572	injured	T169	C0332664
27589720	573	577	mice	T015	C0026809
27589720	582	608	oxygen-glucose deprivation	T039	C4236781
27589720	611	624	reoxygenation	T042	C0872293
27589720	626	629	OGD	T039	C4236781
27589720	632	633	R	T042	C0872293
27589720	636	643	injured	T169	C0332664
27589720	644	649	mouse	T015	C0026809
27589720	650	655	brain	T023	C0006104
27589720	656	669	microvascular	T169	C0443258
27589720	670	687	endothelial cells	T025	C0225336
27589720	689	695	bEnd.3	T025	C0225336
27589720	702	709	results	T169	C1274040
27589720	728	742	administration	T061	C1533734
27589720	746	756	ruscogenin	T109,T121,T123	C0073709
27589720	768	777	decreased	T081	C0205216
27589720	782	798	brain infarction	T047	C0751955
27589720	803	808	edema	T184	C0013604
27589720	810	818	improved	T033	C0184511
27589720	819	840	neurological deficits	T033	C0521654
27589720	842	851	increased	T169	C0442805
27589720	852	871	cerebral brain flow	T033	C0428714
27589720	873	876	CBF	T033	C0428714
27589720	879	890	ameliorated	T033	C0184511
27589720	891	908	histopathological	T169	C0243140
27589720	909	915	damage	T037	C0010957
27589720	917	924	reduced	T080	C0392756
27589720	925	935	evans blue	T109,T130	C0015205
27589720	937	939	EB	T109,T130	C0015205
27589720	941	948	leakage	T033	C4281748
27589720	953	964	upregulated	T044	C0041904
27589720	969	979	expression	T045	C1171362
27589720	983	998	tight junctions	T116,T123	C3494363
27589720	1000	1003	TJs	T116,T123	C3494363
27589720	1008	1012	MCAO	T020	C0740391
27589720	1015	1016	R	T037	C3854511
27589720	1019	1026	injured	T169	C0332664
27589720	1027	1031	mice	T015	C0026809
27589720	1044	1054	ruscogenin	T109,T121,T123	C0073709
27589720	1067	1076	treatment	T061	C0087111
27589720	1077	1086	increased	T169	C0442805
27589720	1087	1101	cell viability	T043	C0007620
27589720	1106	1145	trans-endothelial electrical resistance	T081	C1547024
27589720	1147	1151	TEER	T081	C1547024
27589720	1153	1158	value	T081	C1522609
27589720	1160	1169	decreased	T081	C0205216
27589720	1170	1188	sodium fluorescein	T109,T121,T130	C0147866
27589720	1189	1196	leakage	T033	C4281748
27589720	1202	1211	modulated	T082	C0443264
27589720	1216	1219	TJs	T116,T123	C3494363
27589720	1220	1230	expression	T045	C1171362
27589720	1234	1237	OGD	T039	C4236781
27589720	1240	1241	R	T042	C0872293
27589720	1251	1263	bEnd.3 cells	T025	C0225336
27589720	1275	1285	ruscogenin	T109,T121,T123	C0073709
27589720	1291	1300	inhibited	T052	C3463820
27589720	1305	1315	expression	T045	C1171362
27589720	1319	1333	interleukin-1β	T116,T129	C0021753
27589720	1335	1340	IL-1β	T116,T129	C0021753
27589720	1346	1355	caspase-1	T116,T126	C0534519
27589720	1361	1369	markedly	T080	C0522501
27589720	1370	1380	suppressed	T169	C1260953
27589720	1385	1395	expression	T045	C1171362
27589720	1399	1478	Nucleotide-binding domain (NOD)-like receptor family, pyrin domain containing 3	T116,T123	C4255055
27589720	1480	1485	NLRP3	T116,T123	C1528260
27589720	1491	1521	thiredoxin-interactive protein	T116,T123	C1448239
27589720	1523	1528	TXNIP	T116,T123	C1448239
27589720	1530	1537	in vivo	T062	C0681829
27589720	1542	1550	in vitro	T062	C0681828
27589720	1565	1575	ruscogenin	T109,T121,T123	C0073709
27589720	1576	1585	decreased	T081	C0205216
27589720	1586	1609	reactive oxygen species	T123,T196	C0162772
27589720	1611	1614	ROS	T123,T196	C0162772
27589720	1616	1626	generation	T052	C3146294
27589720	1631	1640	inhibited	T052	C3463820
27589720	1645	1692	mitogen-activated protein kinase (MAPK) pathway	T043	C1518102
27589720	1696	1699	OGD	T039	C4236781
27589720	1702	1703	R	T042	C0872293
27589720	1713	1725	bEnd.3 cells	T025	C0225336
27589720	1731	1739	findings	T033	C0243095
27589720	1757	1765	insights	T041	C0233820
27589720	1775	1784	potential	T080	C3245505
27589720	1785	1796	application	T058	C0185125
27589720	1805	1815	prevention	T061	C0199176
27589720	1820	1829	treatment	T061	C0087111
27589720	1833	1848	ischemic stroke	T047	C0948008